Key Takeaways
- Soft quarter, one-off charges: Revenue declined seasonally while EBITDA margin fell 560 bps to 17.8%, burdened by a INR10.48 crore ECL provision, mark-to-market losses, and higher employee costs from new facility hires.
- U.K. price erosion is the core worry: High single-digit erosion on Rx products, driven by oversupply as tariff uncertainty pushed competitors into the market, caused a sharp YoY revenue drop. Management calls the erosion abnormal but expects it to persist through the year.
- U.S. and new products provide the offset: U.S. growth is driven by new launches in digestive and pain management, while 4 high-margin liquid products launched in the U.K. will improve profitability sequentially even if top-line contribution is modest.
- Order book visibility is back-end loaded: Of the $220 million order book, $45–50 million in execution begins from October onward, meaning a substantial portion will not contribute a full year of revenue in FY26.
- What to watch next quarter: Whether the promised Q2 demand recovery materializes in the U.K., the pace of sequential margin improvement now that one-off charges are cleared, and any resolution on U.S. tariff uncertainty that has frozen new contract visibility.
U.K. Market: Price Erosion and Portfolio Shift
- Abnormal price erosion: High single-digit erosion hit a few Rx products, driven by oversupply and less demand. Management attributes this to global tariff uncertainty causing companies, including "probably the top 20 Indian companies," to refocus into different geographies and engage in desperate selling.
- Rx volatility is structural: The Rx portion, 40% of the U.K. portfolio, is inherently volatile in demand and supply. Currently, oversupply coincides with weaker demand, making some products unviable. Price erosion on Rx can happen dramatically and quickly.
- Seasonal trough amplified the pain: Q1 is the weakest quarter seasonally in the U.K., and the seasonal lull compounded the pricing pressure to produce a sharp YoY decline.
- Recovery path is sequential, not immediate: Q2 will be "much better" than Q1, Q3 better than Q2, and Q4 between Q2 and Q3. New product launches are high-value, not high-volume, so they will add more to the bottom line than the top line.
- Full-year U.K. outlook is flattish: Despite the sequential recovery, the U.K. market overall is expected to be flattish for the year, as pricing pressure offsets volume gains.
- Portfolio evolution toward niche molecules: Management aims to shift the Rx portfolio toward more complex and niche molecules that are less prone to commoditization, making it "much more robust and profitable" over the next 1 to 1.5 years.
Mark Saldanha: "The historic products of Rx will definitely be more volatile, and the newer molecules will be much more profitable. So, I guess we have to just stay one step ahead of the curve."
U.S. Market: Tariff Overhang and Contract Stability
- OTC dominance limits pricing volatility: 90% of the U.S. business is OTC, so contracts are intact with no pricing volatility like that seen in the U.K.
- Growth driven by new launches: Revenue growth came from new product launches in the digestive and pain management segments.
- Tariff uncertainty is freezing new contract visibility: While pharmaceuticals are exempted from tariffs, the lack of clarity has dragged for three months, and visibility on new contracts will only come when tariffs "outplay themselves."
- Indirect demand impact from consumer caution: Even without direct tariffs, consumers are more reserved in spending, buying smaller pack sizes (24-count instead of 100-count) due to rising essential costs, which impacts demand.
- Contingency planning is limited: Existing contracts have force majeure provisions for abnormally high tariffs, which would require renegotiation. Current U.S. manufacturing capacity covers only solid oral dosage and cannot fully compensate for the India-manufactured portfolio, though the company would not shy away from additional U.S. investment if needed.
Mark Saldanha: "But today, it does not make sense for us to panic because literally, I don't think anyone knows what's going to happen tomorrow."
Margins: One-Off Hits and Sequential Recovery
- Two one-off charges distorted the quarter: An expected credit loss provision of INR10.48 crores for the emerging market division and a mark-to-market provision of INR6.2 crores from forward contracts for GBP exports together accounted for the bulk of the margin decline.
- Employee costs stepped up structurally: Additional recruitment for the new Goa facility raised employee expenses; management says no additional hiring is planned, so this step-up should not recur.
- Gross margin improved despite the noise: Liquidation of high-cost inventories and benefits from softening input costs drove gross margin improvement, and management expects gross margins to remain healthy.
- Sequential improvement is promised, but YoY will be flattish: EBITDA margins will improve quarter-on-quarter as one-offs clear and new high-margin products contribute, but year-on-year margins will be "more flattish, somewhere around there" due to persistent U.K. pricing pressure.
- Current-year margin anchor: Management's priority is sustaining last year's margins, with an expectation of landing "somewhere between last year margin and the 17%" (the 17.8% excluding ECL).
Order Book and Revenue Trajectory
- Back-end loaded execution: Of the $220 million order book, $45–50 million in execution begins in October/November/December, meaning a substantial amount will not see a full year of revenue in FY26.
- FY26 revenue target: The company expects to be "very close to INR3,000 crores or maybe shy away from INR3,000 crores" but will still grow over last year.
- Australia/New Zealand timing reversal: Q1 was subdued because retailers lifted stocks in Q4 ahead of the Australian winter; this inventory lull should reverse from Q2 onward, and the full year will show a better number than the previous year.
- Teva facility ramp: The acquired facility is progressing month-on-month toward the aim of reaching INR800-odd crores in revenue.
Strategic Expansion and Capacity
- Goa facility near ready: The new facility is structurally near ready and focused on enhancing operational efficiencies and scaling capacity for multi-dosage forms including tablets, capsules, liquids, creams, and ointments.
- Regulatory milestones achieved: The company received an EIR from the U.S. FDA for the Time-Cap Laboratories inspection and secured 3 regulatory approvals from the U.S. FDA and U.K. MHRA during the quarter.
- Organic Europe entry is a medium-term story: The company is exploring organic entry into European markets including Germany, but this is a "medium- to long-term objective." India is also being explored as a market.
- India-U.K. FTA has zero impact: Management was explicit that a potential free trade agreement between India and the U.K. would have no impact on Marksans.
Mark Saldanha: "So, these uncertainties are the ones that are most unpredictable and difficult to answer. And I guess the market is -- I mean, we don't have a crystal ball."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| U.K. sequential recovery | Q2 "much better" than Q1, Q3 better than Q2, Q4 between Q2 and Q3 | Through FY26 |
| U.K. full-year revenue | Flattish | FY26 |
| U.S. growth | Will grow; contracts are in place | FY26 |
| FY26 revenue | "Very close to INR3,000 crores or maybe shy away," still growing over last year | FY26 |
| FY26 EBITDA margin | "Somewhere between last year margin and the 17%" (17.8% excluding ECL) | FY26 |
| Gross margins | Will continue to be healthy | Ongoing |
| Order book execution | $45–50 mn of $220 mn order book execution begins | October–December 2025 |
| Teva facility revenue | Aim to reach INR800-odd crores | No date (progressing month-on-month) |
| U.K. Rx portfolio evolution | Portfolio to become "much more robust and profitable" via complex, niche molecules | 1 to 1.5 years |
| Organic Germany entry | Launching organically | Medium- to long-term (no date) |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Operating revenue | ₹620 cr, +5% YoY vs ₹590.6 cr |
| U.S. and North America revenue | ₹327.6 cr, +30.6% YoY |
| U.K. and EU formulation revenue | ₹203.8 cr |
| Australia and New Zealand revenue | ₹57 cr |
| Rest of world revenue | ₹31.6 cr |
| Gross profit | ₹358.2 cr, +8.9% YoY |
| Gross margin | 57.8%, expanded 209 bps YoY from 55.7% |
| EBITDA | ₹100.1 cr |
| EBITDA margin | 16.1%, decreased 560 bps YoY |
| EBITDA margin excluding one-time ECL provision | ~17.8% (per an analyst's math) |
| One-time expected credit loss provision | ₹10.48 cr for emerging market division |
| Mark-to-market provision on forward contracts | ₹6.2 cr for GBP exports to U.K. |
| Order book | $220 million |
| Order book execution starting Oct–Dec 2025 | $45 million to $50 million |
| Teva facility revenue run-rate | trending towards ₹500 cr, up from ₹400-odd cr in Q4 FY25 |
| Teva facility revenue potential | ₹800-odd cr, with 40% additional utilization available |
| U.K. portfolio split | 60% OTC, 40% Rx |
| U.S. portfolio split | 90% OTC, 10% Rx |
| U.K. share of total revenue | 40% to 45% |
| U.S. manufacturing share of revenue | ~35% to 40% manufactured in U.S., rest in India |
| Tariff on raw materials imported from China | 20% |
| Regulatory approvals received in Q1 | 3 from U.S. FDA and U.K. MHRA |
| High-margin liquid products launched in U.K. | 4 |